Ted Cruz's regulatory outsourcing plan for the FDA stirs controversy

Ted Cruz's plan to essentially outsource the drug approval process to other countries through a new reciprocal approval approach has been stirring a lot of discussion online. Vox starts with a largely upbeat tone on the prospect of faster approvals for new drugs, then turns to some key criticisms. "This would completely marginalize the FDA," said Aaron Kesselheim, a professor of medicine at Harvard Medical School. "It would allow the decision-making in other countries to have full power over the market in the United States." It would also largely eliminate the FDA's final word on approvals, giving Congress the right to override any of its decisions by a majority vote. Story

Suggested Articles

An FDA panel has narrowly backed the approval of Mallinckrodt’s terlipressin for a type of kidney failure that affects patients with cirrhosis.

A new biotech has come out of stealth with a funding round that includes “celebrity investors in artificial intelligence” as it aims to tackle aging.

GSK filed for patents on the lentiviral stable cell line technology before selling its rare disease gene therapy portfolio to Orchard in 2018.